UroMark Test

Bladder cancer

Bladder cancer affects 11,000 individuals in the UK and over 100,000 in Europe every year. For most people, the first sign of bladder cancer is blood in urine which is called haematuria.

Frequently, visible and non-visible haematuria is also present with non-cancer related conditions such as urinary infection. This means that the diagnosis of bladder cancer is often delayed.

Read more about bladder cancer.

UroMark Test

The UroMark test is a highly sensitive test for bladder cancer developed by the Kelly:Feber Lab. The test is 'non-invasive' which means that it is

performed on a urine sample and avoids the traditional technique of having to pass an instrument along the urethra (or water pipe) to visualise the interior bladder.


The UroMark test is uses the latest technology to analyse over 150 cancer related changes to DNA of cells present in urine. Our results to date show that UroMark can detect bladder cancer with high certainty and is able to differentiate between bladder cancer and non-cancer conditions such as urinary infection.

Clinical testing

The UroMark test is currently in Phase III validation which is a stage before it can be made available for clinical use. The trials are funded by the Medical Research Council and will complete in 2017.

Already a number of clinical studies have been completed and show that the UroMark test detects almost all cancers.


Learn more about current clinical trials.

What does the test involve?

At this time the test is only available in one of our clinical studies. Patients are asked to provide a urine sample. The sample can be provided from home or their doctors surgery and is collected using a specially developed UroMark collection kit which is simply posted to a receiving laboratory for testing.

Who has developed UroMark?

UroMark has been developed by the Kelly:Feber Lab at University College London. Funding for UroMark has been obtained from the UCLH Biomedical research Centre (National Institute for Health Research), The Medical Research Council, Cancer Research UK, The Urology Foundation and The Rosetrees Trust.

Relevant Publications

  1. Tan WS, Rodney S, Lamb B, Feneley M, Kelly J Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016 Jun;47:22-31. doi: 10.1016/j.ctrv.2016.05.002. Epub 2016 May 10.

  2. Feber A, Arya M, De Winter P, Muhammad S, Nigam R, Malone PR, Tan WS, Rodney S, Lechner M, Freeman A, Jameson C, Muneer A, Beck S, Kelly JD. Whole exome sequencing identified novel CSN1 somatic mutations in penile squamous cell carcinoma. Cancer Res. 2016 Aug 15;76(16):4720-7.

  3. P. Gurung, A. Veerakumarasivam, M. Williamson, N. Counsell, N.D.James W.S. Tan, A. feber, S. Crabb, S. Short, A.Freeman, T.Powles, P. Hoskin, C. West. J.D Kelly. Loss of Expression of the Tumour Suppressor Gene AIMP3 Predicts Survival Following Radiotherapy in Muscle-Invasive Bladder Cancer. Int J Cancer. 2015 Feb 1;136(3):709-20. doi: 10.1002/ijc.29022. Epub 2014 Jul 22.

  4. Feber A, Arya M, de Winter P, Saqib M, Nigam R, Malone PR, Tan WS, Rodney S, Lechner M, Freeman A, Jameson C, Muneer A, Beck S, Kelly JD. Epigenetics markers of metastasis and HPV induced tumourigenesis in penile cancer.Clin Cancer Res. 2014 Dec 23. pii: clincanres.1656.2014.[Epub ahead of print]

  5. Feber A, Guilhamon P, Lechner M, Fenton T, Wilson GA, Thirlwell C , Morris TJ , Flanagan AM, Teschendorff AE , Kelly JD , Beck S. Using high-density DNA methylation arrays to profile copy number alterations. Genome Biol. 2014 Feb 3;15(2):R30. PubMed PMID: 24490765. Epub 2014/02/05. Eng.

  6. Patel N, Arya M, Muneer A, Powles T, Sullivan M, Hines J, Kelly J. Molecular aspects of upper tract urothelial carcinoma. Urol Oncol. 2013 Feb 18. doi:pii: S1078-1439(12)00348- 1. 10.1016/j.urolonc.2012.10.002.

  7. Kelly JD, Dudderidge TJ, Wollenschlaeger A, Okoturo O, Burling K, Tulloch F, Halsall I, Prevost T, Prevost AT, Vasconcelos JC, Robson W, Leung Y, Vasdev N, Pickard RS, Williams GH, Stoeber K. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of mcm5 and nuclear matrix protein 22. PLoS One. 2012;7(7):e40305. Epub 2012 Jul 9.

  8. Kelly JD, Fawcett D, Goldberg L. Assessment and investigation of non-visible haematuria in the primary care setting. BMJ 2009;338:a3021

  9. Abhi Veerakumarasivam, Leonard D. Goldstein, Kasra Saeb-Parsy, Helen E. Scott, Anne Warren, Natalie P. Thorne, Ian G. Mills, Ashok Venkitaraman, David E. Neal and John D. Kelly. AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. Cell Cycle. 2008 Nov. 7;22 :27 - 35

  10. Veerakumarasivam A, Warren A, Wallard MJ, Scott HE, Neal DE, Collins VP and Kelly JD. High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53.Clin Cancer Res. 2008 May 1;14(9):2527-34.

  11. Rodgers MA, Hempel S, Aho T, Kelly JD, Kleijnen J, Westwood M. Diagnostic tests used in the investigation of adult haematuria: A systematic review. BJU Int. 2006 Dec;98(6):1154-60.

  12. Rodgers M, Nixon J, Hempel S, Kelly JD et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006; 10: 1–276 13. Kelly JD, M Westwood M, Neal DE. Does the NMP22 bladder check test increase the accuracy of cystoscopy? Nature Clinical Practice Urol. 2005 Jul 2;7: 2-3